Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI (clinicaltrials.gov) - Sep 2, 2026 - P1/2 | N=40 | Not yet recruiting | Sponsor: Peking University People's Hospital
New P1/2 trial • Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation
|